These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 8928243)

  • 41. The relationship among lower urinary tract symptoms, prostate specific antigen and erectile dysfunction in men with benign prostatic hyperplasia: results from the proscar long-term efficacy and safety study.
    Paick SH; Meehan A; Lee M; Penson DF; Wessells H
    J Urol; 2005 Mar; 173(3):903-7. PubMed ID: 15711315
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Therapeutic effects of finasteride in benign prostatic hyperplasia: a randomized double-blind controlled trial.
    Yu HJ; Chiu TY; Lai MK
    J Formos Med Assoc; 1995; 94(1-2):37-41. PubMed ID: 7542109
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The effect of finasteride on prostate volume, urinary flow rate and symptom score in men with benign prostatic hyperplasia.
    Nacey JN; Meffan PJ; Delahunt B
    Aust N Z J Surg; 1995 Jan; 65(1):35-9. PubMed ID: 7529489
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia.
    Marks LS; Partin AW; Gormley GJ; Dorey FJ; Shery ED; Garris JB; Subong EN; Stoner E; deKernion JB
    J Urol; 1997 Jun; 157(6):2171-8. PubMed ID: 9146609
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term treatment with finasteride in men with symptomatic benign prostatic hyperplasia: 10-year follow-up.
    Lam JS; Romas NA; Lowe FC
    Urology; 2003 Feb; 61(2):354-8. PubMed ID: 12597947
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treating benign prostatic hyperplasia with finasteride in Chinese men: one-year experience.
    Chueh SC; Yu HJ; Chiu TY; Huang CY; Lai MK
    J Formos Med Assoc; 1996 Aug; 95(8):650-2. PubMed ID: 8870441
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia.
    Stoner E
    Urology; 1994 Mar; 43(3):284-92; discussion 292-4. PubMed ID: 7510911
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Finasteride in the treatment of benign prostatic hyperplasia. A urodynamic evaluation.
    Kirby RS; Bryan J; Eardley I; Christmas TJ; Liu S; Holmes SA; Vale JA; Shanmuganathan K; Webb JA
    Br J Urol; 1992 Jul; 70(1):65-72. PubMed ID: 1379107
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Finasteride for the treatment and control of benign prostatic hyperplasia: summary of phase III controlled studies. The Finasteride Study Group.
    Grino P; Stoner E
    Eur Urol; 1994; 25 Suppl 1():24-8. PubMed ID: 7507052
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy, tolerability, and effect on health-related quality of life of finasteride versus placebo in men with symptomatic benign prostatic hyperplasia: a community based study. CUSP Investigators. Community based study of Proscar.
    Byrnes CA; Morton AS; Liss CL; Lippert MC; Gillenwater JY
    Clin Ther; 1995; 17(5):956-69. PubMed ID: 8595647
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. The Finasteride Study Group.
    Prostate; 1993; 22(4):291-9. PubMed ID: 7684524
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Estrogen reduction by aromatase inhibition for benign prostatic hyperplasia: results of a double-blind, placebo-controlled, randomized clinical trial using two doses of the aromatase-inhibitor atamestane. Atamestane Study Group.
    Radlmaier A; Eickenberg HU; Fletcher MS; Fourcade RO; Reis Santos JM; van Aubel OG; Bono AV
    Prostate; 1996 Oct; 29(4):199-208. PubMed ID: 8876703
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasia.
    Kaplan SA; Holtgrewe HL; Bruskewitz R; Saltzman B; Mobley D; Narayan P; Lund RH; Weiner S; Wells G; Cook TJ; Meehan A; Waldstreicher J;
    Urology; 2001 Jun; 57(6):1073-7. PubMed ID: 11377309
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of finasteride is maintained in patients with benign prostatic hyperplasia treated for 5 years. The North American Finasteride Study Group.
    Hudson PB; Boake R; Trachtenberg J; Romas NA; Rosenblatt S; Narayan P; Geller J; Lieber MM; Elhilali M; Norman R; Patterson L; Perreault JP; Malek GH; Bruskewitz RC; Roy JB; Ko A; Jacobsen CA; Stoner E
    Urology; 1999 Apr; 53(4):690-5. PubMed ID: 10197842
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term urodynamic effects of finasteride in benign prostatic hyperplasia: a pilot study.
    Kirby RS; Vale J; Bryan J; Holmes K; Webb JA
    Eur Urol; 1993; 24(1):20-6. PubMed ID: 7689971
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetic parameters as a potential predictor of response to pharmacotherapy in benign prostatic hyperplasia: a preclinical trial using dynamic contrast-enhanced MRI.
    Jia G; Heverhagen JT; Henry H; Polzer H; Baudendistel KT; von Tengg-Kobligk H; Levine AL; Rosol TJ; Knopp MV
    Magn Reson Imaging; 2006 Jul; 24(6):721-5. PubMed ID: 16824967
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Improvement of pressure flow parameters with finasteride is greater in men with large prostates. Finasteride Urodynamics Study Group.
    Abrams P; Schäfer W; Tammela TL; Barrett DM; Hedlund H; Rollema HJ; Matos-Ferreira A; Nordling J; Bruskewitz R; Andersen JT; Hald T; Miller P; Kirby R; Mustonen S; Cannon A; Jacobsen CA; Gormley GJ; Malice MP; Bach MA
    J Urol; 1999 May; 161(5):1513-7. PubMed ID: 10210385
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Maximum efficacy of finasteride is obtained within 6 months and maintained over 6 years. Follow-up of the Scandinavian Open-Extension Study. The Scandinavian Finasteride Study Group.
    Ekman P
    Eur Urol; 1998; 33(3):312-7. PubMed ID: 9555559
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Transition zone volume and transition zone ratio: predictor of uroflow response to finasteride therapy in benign prostatic hyperplasia patients.
    Tewari A; Shinohara K; Narayan P
    Urology; 1995 Feb; 45(2):258-64; discussion 265. PubMed ID: 7531900
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-term (7 to 8-year) experience with finasteride in men with benign prostatic hyperplasia.
    Vaughan D; Imperato-McGinley J; McConnell J; Matsumoto AM; Bracken B; Roy J; Sullivan M; Pappas F; Cook T; Daurio C; Meehan A; Stoner E; Waldstreicher J
    Urology; 2002 Dec; 60(6):1040-4. PubMed ID: 12475666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.